More on MANE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (9/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NY:MANE)
Delayed: 113.85 +4.34 (3.96%)
Prev. Close $109.51  
Open$111.05 
52 Wk High$ 
52 Wk Low$ 
Day High$116.09 
Day Low$110.25 
P/E N/A  
EPS$ 
Volume170,751 

Friends, Peers and Foes (?): LLY, ACHV TARS (more...)

Jul 17, 2026 07:30 AM Veradermics presents Phase 2/3 hair loss drug data at AAD meeting
Jul 17, 2026 07:30 AM Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Jul 15, 2026 08:55 AM Form 8-K Veradermics, Inc For: Jul 15
Jul 15, 2026 07:00 AM Veradermics reports positive Phase 2 results for oral hair loss drug
Jul 15, 2026 07:00 AM Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
Jul 15, 2026 02:14 AM B.Riley Starts Veradermics (MANE) at Buy
Jul 14, 2026 06:54 PM Veradermics to host call on Phase 2 hair loss drug trial results
Jul 14, 2026 06:54 PM Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Jun 25, 2026 07:25 AM Veradermics (MANE) Reiterated at Overweight by Cantor Fitzgerald After Investor Dinner
Jun 16, 2026 07:17 AM LifeSci Capital Starts Veradermics (MANE) at Outperform
View All Articles

Entities mentioned with MANE

View All Entities